Venus Remedies Gets New Market Breakthroughs, Including its First Generic Entry in Indonesia
Venus Remedies marks a key global milestone with its first generic antibiotic approval in Indonesia, strengthening its critical care presence across international markets.
We are proud to share that Venus Remedies received new marketing authorizations, including a significant regulatory accomplishment in Indonesia for its antibiotic combination, Ceftazidime + Avibactam.
This marks Venus Remedies’ entry in the anti-infective segment in Indonesia, and the product will become the first generic version of Ceftazidime + Avibactam launched. It is a key step in executing its international growth strategy and strengthening its presence across ASEAN markets.
"The approval of Ceftazidime + Avibactam in Indonesia is an important regulatory milestone for Venus Remedies and reflects our continued focus on addressing antimicrobial resistance through clinically relevant therapies for hospital-based care," said Mr. Saransh Chaudhary, President, Global Critical Care, Venus Remedies.
Expansion in a Key Market
Indonesia is one of the largest pharmaceutical markets in Southeast Asia, where antibiotics play a crucial role due to the high burden of infectious diseases and rising focus on antimicrobial stewardship. Ceftazidime + Avibactam is expected to improve access to advanced anti-infective therapy in hospital and critical-care settings.
Aditi K. Chaudhary, President, International Business, Venus Remedies, emphasized that Indonesia remains a priority market for Venus Remedies. She said, “This approval expands our footprint beyond oncology into critical anti-infective therapies, underscoring our long-term commitment to building a scalable and sustainable business in the region.”
Strong Positioning of Venus Remedies
This development also reinforces Venus Remedies’ strong commercial platform across the ASEAN region, where the company is already active in 10 countries and holds more than authorizations for its 370 injectable products.
This sets an important benchmark for our international business and aligns perfectly with our vision to bring high-quality, life-saving injectable therapies to patients around the world. It’s a proud moment that reflects our strategic focus, regulatory expertise, and commitment to global health.
More Significant Market Authorizations:
Continuing its legacy of excellence, Venus Remedies Limited has also secured regulatory approvals for Bendamustine 100 mg in Malaysia, Ceftriaxone + Sulbactam 1.5 g, and Polymyxin B Sulphate 500,000 IU in the Philippines, further strengthening its presence in the ASEAN region.
The company has also received market authorizations for PAXOL 300 mg/50 ml and DOXOL 20 mg/0.5 ml in Sudan, Oxaliplatin 50 mg/10 ml (Prolife) in Costa Rica, Ceftazidime and Cisplatin Venus in Croatia. This is accompanied by approvals for Bortezomib 3.5 mg, Meropenem 500 mg & 1 g in Bahrain, reinforcing its footprint in the GCC market.
These mark a significant step in our strategy to enhance global access to high-quality oncology and critical care products, demonstrating the company’s continued focus on regulatory excellence, portfolio diversification, and commitment to improving accessibility across international markets.
